Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
  • C07C309/63—Esters of sulfonic acids
  • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
  • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
  • C07C309/63—Esters of sulfonic acids
  • C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
  • C07C309/73—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
  • C07C35/21—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a non-condensed ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
  • C07C37/01—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis
  • C07C37/04—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis by substitution of SO3H groups or a derivative thereof
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
  • C07C37/01—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis
  • C07C37/055—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis the substituted group being bound to oxygen, e.g. ether group
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
  • C07C37/01—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis
  • C07C37/055—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis the substituted group being bound to oxygen, e.g. ether group
  • C07C37/0555—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis the substituted group being bound to oxygen, e.g. ether group being esterified hydroxy groups
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
  • C07C37/11—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by reactions increasing the number of carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
  • C07C37/11—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by reactions increasing the number of carbon atoms
  • C07C37/16—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by reactions increasing the number of carbon atoms by condensation involving hydroxy groups of phenols or alcohols or the ether or mineral ester group derived therefrom
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
  • C07C37/50—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by reactions decreasing the number of carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
  • C07C37/68—Purification; separation; Use of additives, e.g. for stabilisation
  • C07C37/70—Purification; separation; Use of additives, e.g. for stabilisation by physical treatment
  • C07C37/84—Purification; separation; Use of additives, e.g. for stabilisation by physical treatment by crystallisation
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
  • C07C39/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
  • C07C41/01—Preparation of ethers
  • C07C41/18—Preparation of ethers by reactions not forming ether-oxygen bonds
  • C07C41/30—Preparation of ethers by reactions not forming ether-oxygen bonds by increasing the number of carbon atoms, e.g. by oligomerisation
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C43/00—Ethers; Compounds having groups, groups or groups
  • C07C43/02—Ethers
  • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
  • C07C43/215—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring having unsaturation outside the six-membered aromatic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C43/00—Ethers; Compounds having groups, groups or groups
  • C07C43/02—Ethers
  • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
  • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C67/00—Preparation of carboxylic acid esters
  • C07C67/28—Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group
  • C07C67/293—Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
  • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
  • C07C69/12—Acetic acid esters
  • C07C69/14—Acetic acid esters of monohydroxylic compounds
  • C07C69/145—Acetic acid esters of monohydroxylic compounds of unsaturated alcohols
  • C07C69/157—Acetic acid esters of monohydroxylic compounds of unsaturated alcohols containing six-membered aromatic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
  • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
  • C07D311/78—Ring systems having three or more relevant rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
  • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
  • C07D311/78—Ring systems having three or more relevant rings
  • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
  • C07F5/02—Boron compounds
  • C07F5/027—Organoboranes and organoborohydrides
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
  • C07F7/02—Silicon compounds
  • C07F7/08—Compounds having one or more C—Si linkages
  • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
  • C07F7/1804—Compounds having Si-O-C linkages
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
  • C07F7/02—Silicon compounds
  • C07F7/08—Compounds having one or more C—Si linkages
  • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
  • C07F7/1804—Compounds having Si-O-C linkages
  • C07F7/1872—Preparation; Treatments not provided for in C07F7/20
  • C07F7/188—Preparation; Treatments not provided for in C07F7/20 by reactions involving the formation of Si-O linkages
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
  • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
  • C07B2200/07—Optical isomers
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
  • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
  • C07B2200/09—Geometrical isomers
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C2601/00—Systems containing only non-condensed rings
  • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
  • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Definitions

• the present disclosure relates to cannabinoid sulfonate ester compounds and the use of the compounds for the preparation of cannabinoids.
• the disclosure also relates to the use of catalysts and catalytic processes for the preparation of cannabinoids using the cannabinoid sulfonate esters as precursors.
• CBD cannabidiol
• THC tetrahydrocannabinol
• CBD-rich strains of cannabis has been developed and used medicinally for treating inflammation, AIDS, ALS, Alzheimer’s disease, anorexia, anxiety, arthritis, asthma, cancer, depression, diabetes, epilepsy, glaucoma, migraine, nausea, neuropathic pain, Parkinson’s disease, just to name a few.
• CBD cannabidiol
• CBD Tetrahydrocannabivarin
• the demand for pure, single component CBD and other cannabinoids is growing rapidly and as the demand for medicinal and legal recreational cannabis continues to grow, the amount of cannabis plants grown and harvested specifically for the extraction of cannabinoids will diminish.
• the advantage of synthesized cannabinoids relative to the products extracted from medicinal cannabis or hemp plants is the stability of supply, and control over quality and scalability.
• the output can always be adjusted depending on demand.
• Extracted cannabis resin contains more than 150 cannabinoid products, in addition to other compounds present in the plant. Even for cannabis plants with high CBD or THC content, the process of extracting and purifying the products is laborious, time consuming and only small amounts of the desired components relative to the amount of plant material is realized.
• the cannabis or hemp crop and quality can be impacted by drought, pests, pesticides and inclement weather.
• the present invention in some aspects, describes an approach to developing synthetic cannabinoids that focuses on the use of cheap and commercially available chemicals and use of these chemicals to prepare stable precursors that can be transformed into the desired cannabinoid product on demand.
• Such commercially available chemicals include, but are not limited to limonene, resorcinol and their derivatives.
• the invention relates to the preparation of new cannabinoid sulfonate ester compounds and the use of such sulfonate ester compounds for the preparation of cannabinoid products using catalysts and catalytic processes to substitute the sulfonate groups.
• the cannabinoid sulfonate esters can be prepared and purified prior to transformation to the desired individual cannabinoid products.
• the cannabinoid sulfonate esters are air-stable and shelf-stable compounds that can be stored, transported and converted into the desired cannabinoid products on demand.
• the present invention relates to cannabinoid sulfonate esters of Formula (I):
• Ri represents a hydrogen atom, a linear or branched alkyl group of any length, possibly substituted, or an alkenyl group of any length, possibly substituted, or an alkynyl group, possibly substituted, or a cycloalkyl group, possibly substituted, or an aryl group, possibly substituted, or an heteroaryl group, possibly substituted, or an OR c group or an NR C 2 group, possibly substituted, with possible and non-limiting substituents of Ri being halogen atoms, OR c , or NR C 2 groups, in which R c is a hydrogen atom or a cyclic, linear or branched alkyl, aryl or alkenyl group.
• the compounds of Formula (I) can be prepared and isolated prior to use.
• the present disclosure also relates to cannabinoid sulfonate esters of Formula (II):
• Ri represents a hydrogen atom, a linear or branched alkyl group of any length, possibly substituted, or an alkenyl group of any length, possibly substituted, or an alkynyl group, possibly substituted, or a cycloalkyl group, possibly substituted, or an aryl group, possibly substituted, or an heteroaryl group, possibly substituted, or an OR c group or an NR C 2 group, possibly substituted, with possible and non-limiting substituents of Ri being halogen atoms, OR c , or NR C 2 groups, in which R c is a hydrogen atom or a cyclic, linear or branched alkyl, aryl or alkenyl group;
• R 2 and R 3 represents a linear or branched alkyl group of any length, possibly substituted, or an alkenyl group of any length, possibly substituted, or an alkynyl group, possibly substituted, or a cycloalkyl group, possibly substituted, or an aryl group, possibly substituted, or an heteroaryl group, possibly substituted, or an acyl group, possibly substituted, and one or more of the carbon atoms in the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl or acyl groups of R 2 and/or R 3 is optionally replaced with a heteroatom selected from the group consisting of O, S, N, P and Si, which, where possible, is optionally substituted with one or more groups.
• the compounds of Formula (II) can be prepared and isolated prior to use.
• the transformations to which the compounds of the invention can be applied include but are not limited to catalytic and non-catalytic carbon-carbon bond forming reactions including Ullman, Suzuki- Miyaura, Negishi, Kumada, Sonogashira and Stille reactions.
• Such carbon-carbon bond forming reactions include the use of compounds of the present disclosure, such as those of Formula (I) and (II) to prepare one or more of the cannabinoid compounds selected from the group consisting of: Formula (III):
• R 2 and R 3 represents a linear or branched alkyl group of any length, possibly substituted, or an alkenyl group of any length, possibly substituted, or an alkynyl group, possibly substituted, or a cycloalkyl group, possibly substituted, or an aryl group, possibly substituted, or an heteroaryl group, possibly substituted, or an acyl group, possibly substituted, and one or more of the carbon atoms in the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl or acyl groups of R 2 and/or R 3 is optionally replaced with a heteroatom selected from the group consisting of O, S, N, P and Si, which, where possible, is optionally substituted with one or more groups; and R 4 represents a hydrogen atom, a linear or branched alkyl group of any length, possibly substituted, or an alkenyl group of any length, possibly substituted, or an alkynyl group, possibly substitute
• the invention provides a process for the catalytic preparation of a compound of Formula (III), Formula (IV), Formula (V) or Formula (VI) from a compound of Formula (I) or Formula (II). In some other aspects the invention provides a process for the non-catalytic preparation of a compound of Formula (III), Formula (IV), Formula (V) or Formula (VI) from a compound of Formula (I) or Formula (II).
• the process for the preparation of a compound of Formula (III), Formula (IV), Formula (V) or Formula (VI) from a compound of Formula (I) or Formula (II) pursuant to the invention uses a boron containing compound such as R 4 -B(OH) 2 , R 4 -B(OR) 2 or R 4 -BF 3 K.
• a Grignard compound such as R 4 -MgX is used to prepare Formula (III), Formula (IV), Formula (V) or Formula (VI).
• an organozinc compound such as R 4 -ZnX is used to prepare Formula (III), Formula (IV), Formula (V) or Formula (VI).
• the invention provides a compound or composition comprising: Formula (III), Formula (IV), Formula (V) or Formula (VI) where the compounds, or compositions as the case may be pure isomers or a mixture of isomers.
• the compounds and compositions of the invention comprise all isomers of compounds of Formula (I) and Formula (II). In some other embodiments it provides a mixture of isomers of compounds of Formula (I) and Formula (II). In yet some other embodiment it provides single isomers of compounds of Formula (I) and Formula (II). In some other aspects, the invention provides processes and methods for producing any of the foregoing.
• the present invention also includes, compositions, methods of producing the compound and compositions comprising the compounds of the invention, kits comprising any one or more of the components of the foregoing, optionally with instructions to make or use same and uses of any of the foregoing.
• FIG. 1 shows the scheme for the preparation of cannabidiol (CBD);
• Figure 2 shows the X-ray crystal structure of 2-((1 R,6R)-3-methyl-6-(prop-1 -en-2- yl)cyclohex-2-enyl)benzene-1 ,3,5-triol;
• Figure 3 shows the X-ray crystal structure of 3,5-dihydroxy-4-((1 R,6R)-3-methyl-6- (prop-1 -en-2-yl)cyclohex-2-enyl)phenyl trifluoromethanesulfonate;
• Figure 4 shows the X-ray crystal structure of Cannabidiol
• Figure 5 shows the 1 H NMR spectrum of 2-((1 R,6R)-3-methyl-6-(prop-1-en-2- yl)cyclohex-2-enyl)benzene-1 ,3,5-triol;
• Figure 6 shows the 1 H NMR spectrum of 3,5-dihydroxy-4-((1 R,6R)-3-methyl-6- (prop-1 -en-2-yl)cyclohex-2-enyl)phenyl trifluoromethanesulfonate;
• Figure 7 shows the 1 H NMR spectrum of 4-((1 R,6R)-3-methyl-6-(prop-1-en-2- yl)cyclohex-2-enyl)-3,5-bis(trimethylsilyloxy)phenyl trifluoromethanesulfonate;
• FIG. 8 shows the 1 H NMR spectrum of Cannabidiol (CBD).
• FIG. 9 shows the 1 H NMR spectrum of Tetrahydrocannabinol (THC).
• Figure 10 shows the 1 H NMR spectrum of (5-heptyl-2-((1 R,6R)-3-methyl-6-(prop-1- en-2-yl)cyclohex-2-enyl)-1 ,3-phenylene)bis(oxy)bis(trimethylsilane);
• FIG 11 shows the 1 H NMR spectrum of Cannabidiphorol (CBDP);
• Figure 12 shows the 1 H NMR spectrum of Tetrahydrocannabiphorol (THCP);
• Figure 13 shows the X-ray crystal structure of 2-((1 S,6R)-3-methyl-6-(prop-1-en-2- yl)cyclohex-2-enyl)benzene-1 ,3,5-triol;
• Figure 14 shows the 1 H NMR spectrum of 2-((1 S,6R)-3-methyl-6-(prop-1-en-2- yl)cyclohex-2-enyl)benzene-1 ,3,5-triol;
• Figure 15 shows the 1 H NMR spectrum of 4-((1 S,6R)-3-methyl-6-(prop-1-en-2- yl)cyclohex-2-enyl)-3,5-bis(trimethylsilyloxy)phenyl trifluoromethanesulfonate.
• alkyl as used herein means straight and/or branched chain, saturated alkyl radicals containing one or more carbon atoms and includes (depending on the identity) methyl, ethyl, propyl, isopropyl, n-butyl, s-butyl, isobutyl, t-butyl, 2,2- dimethylbutyl, n-pentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, n-hexyl and the like.
• alkenyl as used herein means straight and/or branched chain, unsaturated alkyl radicals containing two or more carbon atoms and one to three double bonds, and includes (depending on the identity) vinyl, allyl, 2-methylprop-1 - enyl, but-1 -enyl, but-2-enyl, but-3-enyl, 2-methylbut-1 -enyl, 2-methylpent-1-enyl, 4- methylpent-1-enyl, 4-methylpent-2-enyl, 2-methylpent-2-enyl, 4-methylpenta-1 ,3- dienyl, hexen-1-yl and the like.
• alkynyl as used herein means straight and/or branched chain, unsaturated alkyl radicals containing two or more carbon atoms and one to three triple bonds, and includes (depending on the identity) acetylynyl, propynyl, but-1 - ynyl, but-2-ynyl, but-3-ynyl, 3-methylbut-1 -enyl, 3-methylpent-1 -ynyl, 4-methylpent-1 - ynyl, 4-methylpent-2-ynyl, penta-1 ,3-di-ynyl, hexyn-1 -yl and the like.
• alkoxy as used herein means straight and/or branched chain alkoxy group containing one or more carbon atoms and includes (depending on the identity) methoxy, ethoxy, propyloxy, isopropyloxy, t-butoxy, heptoxy, and the like.
• cycloalkyl as used herein means a monocyclic, bicyclic or tricyclic saturated carbocylic group containing three or more carbon atoms and includes (depending on the identity) cyclopropyl, cyclobutyl, cyclopentyl, cyclodecyl and the like.
• aryl as used herein means a monocyclic, bicyclic or tricyclic aromatic ring system containing at least one aromatic ring and 6 or more carbon atoms and includes phenyl, naphthyl, anthracenyl, 1 ,2-dihydronaphthyl, 1 ,2,3,4- tetrahydronaphthyl, fluorenyl, indanyl, indenyl and the like.
• heteroaryl as used herein means a monocyclic, bicyclic or tricyclic ring system containing one or two aromatic rings and 5 or more atoms of which, unless otherwise specified, one, two, three, four or five are heteromoieties independently selected from N, NH, N(alkyl), O and S and includes thienyl, furyl, pyrrolyl, pyrididyl, indolyl, quinolyl, isoquinolyl, tetrahydroquinolyl, benzofuryl, benzothienyl and the like.
• halo or“halogen” as used herein means chloro, fluoro, bromo or iodo.
• fluoro-substituted means that at least one, including all, of the hydrogens on the referenced group is replaced with fluorine.
• the suffix“ene” added on to any of the above groups means that the group is divalent, i.e. inserted between two other groups.
• ring system refers to a carbon-containing ring system, that includes monocycles, fused bicyclic and polycyclic rings, bridged rings and metalocenes. Where specified, the carbons in the rings may be substituted or replaced with heteroatoms.
• the present disclosure relates to cannabinoid sulfonate esters of Formula (I) and any stereoisomers or acceptable salts thereof:
• Ri represents a hydrogen atom, a linear or branched alkyl group of any length, possibly substituted, or an alkenyl group of any length, possibly substituted, or an alkynyl group, possibly substituted, or a cycloalkyl group, possibly substituted, or an aryl group, possibly substituted, or an heteroaryl group, possibly substituted, or an OR c group or an NR C 2 group, possibly substituted, with possible and non-limiting substituents of Ri being halogen atoms, OR c , or NR C 2 groups, in which R c is a hydrogen atom or a cyclic, linear or branched alkyl, aryl or alkenyl group.
• Ri represents a hydrogen atom, -OR c , -NR C 2 , fluoro-substituted- (Ci-C 2 o)-alkyl, a (Ci-C 2 o)-alkyl group, a (C 2 -C 2 o)-alkenyl group, a (C 2 -C 2 o)-alkynyl group, a (C3-C 2 o)-cycloalkyl group, a (Ce-Ci4)-aryl group, or a (C5-Ci4)-heteroaryl group, wherein the latter 6 groups are each optionally substituted with one or more halogen atoms (F, Cl, Br or I), -(Ci-C 2 o)-alkyl, a (C 2 -C 2 o)-alkenyl group, a (C 2 -C 20 ,
• Ri represents a hydrogen atom, fluoro-substituted-(Ci-C 2 o)- alkyl, a (Ci-C 2 o)-alkyl group, a (C 2 -C 2 o)-alkenyl group, a (C 2 -C 2 o)-alkynyl group, a (C 3 -C 2 o)-cycloalkyl group, a (C 6 -Ci 4 )-aryl group, a (C 5 -Ci 4 )-heteroaryl group, wherein the latter 6 groups are each optionally substituted with one or more halogen atoms (F, Cl, Br or I), -(Ci-C 2 o)-alkyl, a (C 2 -C 2 o)-alkenyl group, a (C 2 -C 2 o)-alkynyl group, - OR d , or -NR d 2 , wherein R
• Ri represents a hydrogen atom, fluoro-substituted-(Ci-Cio)- alkyl, a (Ci-Cio)-alkyl group, a (C 2 -Cio)-alkenyl group, a (C 2 -Cio)-alkynyl group, a (C 3 -Cio)-cycloalkyl group, a (Ce-Cio)-aryl group, a (C 5 -Cio)-heteroaryl group, wherein the latter 6 groups are each optionally substituted with one or more halogen atoms (F, Cl, Br or I), -(Ci-C 2 o)-alkyl, a (C 2 -C 2 o)-alkenyl group, or a (C 2 -C 2 o)-alkynyl group.
• halogen atoms F, Cl, Br or I
• Ri represents a hydrogen atom, fluoro-substituted-(Ci-C 6 )- alkyl, a (Ci-Ce)-alkyl group, a (C 2 -Ce)-alkenyl group, a (C 2 -Ce)-alkynyl group, a (C 3 - C 6 )-cycloalkyl group, a (Ce)-aryl group, a (C 5 -C 6 )-heteroaryl group, wherein the latter 6 groups are each optionally substituted with one or more halogen atoms (F, Cl, Br or I), or -(Ci-C 2 o)-alkyl.
• halogen atoms F, Cl, Br or I
• Ri represents a hydrogen atom, fluoro-substituted-(Ci-C 6 )- alkyl, a (Ci-Ce)-alkyl group, or a phenyl group, wherein the latter 2 groups are each optionally substituted with one or more halogen atoms (F, Cl, Br or I), or -(C 1 -C 10 )- alkyl.
• Ri represents a hydrogen atom, -CF 3 , or
• the compound of Formula (I) is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
• the compound of the Formula (I) is a compound of Formula (IA)
• LG is any suitable leaving group, such as a halo group, sulphonates, or boronates.
• the boronate leaving group is -B(OR) 2 , where R is H, a (Ci-C 2 o)-alkyl group, a (C 2 -C 2 o)-alkenyl group, a (C 2 -C 2 o)-alkynyl group, a (C 3 - C 2 o)-cycloalkyl group, or a (Ce-Ci 4 )-aryl group.
• the boronate leaving group is -B(OR) 2 , where R is H, a (Ci-C 2 o)-alkyl group (such as a (C 1 -C 10 )- alkyl group) or a (C 6 -Ci 4 )-aryl group (such as a (Ce-Cio)-aryl group).
• R is H, a (Ci-C 2 o)-alkyl group (such as a (C 1 -C 10 )- alkyl group) or a (C 6 -Ci 4 )-aryl group (such as a (Ce-Cio)-aryl group).
• the boronate leaving group is -BF 3 K.
• the leaving group is a triflate, mesylate or tosylate group.
• the present disclosure also relates to cannabinoid sulfonate esters of Formula (II) and any stereoisomers or acceptable salts thereof:
• Ri represents a hydrogen atom, a linear or branched alkyl group of any length, possibly substituted, or an alkenyl group of any length, possibly substituted, or an alkynyl group, possibly substituted, or a cycloalkyl group, possibly substituted, or an aryl group, possibly substituted, or an heteroaryl group, possibly substituted, or an OR c group or an NR C 2 group, possibly substituted, with possible and non-limiting substituents of Ri being halogen atoms, OR c , or NR C 2 groups, in which R c is a hydrogen atom or a cyclic, linear or branched alkyl, aryl or alkenyl group;
• R 2 and R 3 represents a linear or branched alkyl group of any length, possibly substituted, or an alkenyl group of any length, possibly substituted, or an alkynyl group, possibly substituted, or a cycloalkyl group, possibly substituted, or an aryl group, possibly substituted, or an heteroaryl group, possibly substituted, or an acyl group, possibly substituted, and one or more of the carbon atoms in the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl or acyl groups of R 2 and/or R 3 is optionally replaced with a heteroatom selected from the group consisting of O, S, N, P and Si, which, where possible, is optionally substituted with one or more groups.
• the compounds of Formula (II) can be prepared and isolated prior to use.
• Ri in the compound of Formula (II) is as defined in all embodiments for the compound of Formula (I).
• one or more of the carbon atoms in the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl or acyl groups of R 2 and/or R 3 is optionally replaced with a heteroatom selected from the group consisting of O, S, N, P and Si, which, where possible, is optionally substituted with one or more halogen (F, Cl, Br or I), or a -(Ci- C 2 o)-alkyl groups.
• one or more of the carbon atoms in the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl or acyl groups of R 2 and/or R 3 is optionally replaced with a heteroatom selected from the group consisting of O, S, N, P and Si, which, where possible, is optionally substituted with one or more halogen (F, Cl, Br or I), or a -(Ci- Cio)-alkyl groups.
• one or more of the carbon atoms in the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl or acyl groups of R 2 and/or R 3 is optionally replaced with a heteroatom selected from the group consisting of O, S, N, P and Si, which, where possible, is optionally substituted with one or more halogen (F, Cl, Br or I), or a -(Ci- Cio 6 )-alkyl groups.
• R 2 and R 3 independently or simultaneously represent a (Ci-Ce)- alkyl group, a -Si[(Ci-C 6 )-alkyl] 3 group, or a phenyl group. In one embodiment, R 2 and R 3 independently or simultaneously represent a— Si[(Ci - C 6 )-alkyl] 3 group. In one embodiment, R 2 and R 3 independently or simultaneously represent a— Si[(Ci-C 3 )-alkyl] 3 group. In one embodiment, R 2 and R 3 represent a - Si(CH 3 ) 3 group. In one embodiment, the compound of the Formula (II) is a compound of Formula (I I A)
• LG is any suitable leaving group.
• LG is any suitable leaving group. In one embodiment, LG is
• the boronate leaving group is -B(OR) 2 , where R is H, a (Ci- C 2 o)-alkyl group, a (C 2 -C 2 o)-alkenyl group, a (C 2 -C 2 o)-alkynyl group, a (C 3 -C 20 )- cycloalkyl group, or a (Ce-Ci 4 )-aryl group.
• the boronate leaving group is -B(OR) 2 , where R is H, a (Ci-C 2 o)-alkyl group (such as a (C 1 -C 10 )- alkyl group) or a (C 6 -Ci 4 )-aryl group (such as a (Ce-Cio)-aryl group).
• R is H, a (Ci-C 2 o)-alkyl group (such as a (C 1 -C 10 )- alkyl group) or a (C 6 -Ci 4 )-aryl group (such as a (Ce-Cio)-aryl group).
• the boronate leaving group is -BF 3 K.
• R 2 and R 3 represents a linear or branched alkyl group of any length, possibly substituted, or an alkenyl group of any length, possibly substituted, or an alkynyl group, possibly substituted, or a cycloalkyl group, possibly substituted, or an aryl group, possibly substituted, or an heteroaryl group, possibly substituted, or an acyl group, possibly substituted, and one or more of the carbon atoms in the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl or acyl groups of R 2 and/or R 3 is optionally replaced with a heteroatom selected from the group consisting of O, S, N, P and Si, which, where possible, is optionally substituted with one or more groups; and R 4 represents a hydrogen atom, a linear or branched alkyl group of any length, possibly substituted, or an alkenyl group of any length, possibly substituted, or an alkynyl group, possibly substitute
• R 2 and R 3 in the compounds of Formula (III), (IV) (V) and (VI) are as defined in each embodiment for the compounds of Formula (II).
• R 4 represents a hydrogen atom, a (Ci-C 2 o)-alkyl group, a (C 2 - C 2 o)-alkenyl group, a (C 2 -C 2 o)-alkynyl group, a (C 3 -C 2 o)-cycloalkyl group, a (Ce-Ci 4 )- aryl group, wherein the latter 5 groups are each optionally substituted with one or more halogen atoms (F, Cl, Br or I), -(Ci-C 2 o)-alkyl, a (C 2 -C 2 o)-alkenyl group, a (C 2 - C2o)-alkynyl group, (C 6 -Ci 4 )-aryl group, -OR d ,
• R 4 represents a hydrogen atom, a (Ci-C2o)-alkyl group, a (C 2 - C2o)-alkenyl group, a (C 6 -Ci 4 )-aryl group, wherein the latter 3 groups are each optionally substituted with one or more halogen atoms (F, Cl, Br or I), -(Ci-Cio)-alkyl, a (C2-Cio)-alkenyl group, a (C2-Cio)-alkynyl group, or (C 6 -Cio)-aryl group.
• halogen atoms F, Cl, Br or I
• R 4 represents a hydrogen atom, a (Ci-C 2 o)-alkyl group, a (Ce- Cio)-aryl group, wherein the latter 2 groups are each optionally substituted with one or more phenyl groups.
• R 4 represents a hydrogen atom or a (Ci-C2o)-alkyl group optionally substituted with a phenyl group.
• the present disclosure also relates to a process for the production of compounds of Formula (I) comprising first contacting a compound of Formula (VII)
• Compound (IX) is then transformed to a compound of Formula (I) by contacting a compound of Formula (IX) with the required sulfonylating reagent in the presence of a base.
• Compound (I) is then transformed to a compound of Formula (II) by contacting a compound of Formula (I) with a suitable reagent in the presence of a base.
• Suitable acid catalysts include but are not limited to Lewis acids, organic acids and inorganic acids.
• the disclosure also relates to a process for the catalytic and non-catalytic use of compounds of Formula (I) and Formula (II) to prepare cannabinoid compounds of Formula (III):
• R 2 and R 3 represents a linear or branched alkyl group of any length, possibly substituted, or an alkenyl group of any length, possibly substituted, or an alkynyl group, possibly substituted, or a cycloalkyl group, possibly substituted, or an aryl group, possibly substituted, or an heteroaryl group, possibly substituted, or an acyl group, possibly substituted, and one or more of the carbon atoms in the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl or acyl groups of R 2 and/or R 3 is optionally replaced with a heteroatom selected from the group consisting of O, S, N, P and Si, which, where possible, is optionally substituted with one or more groups; and R4 represents a hydrogen atom, a linear or branched alkyl group of any length, possibly substituted, or an alkenyl group of any length, possibly substituted, or an alkynyl group, possibly substitute
• R 2 , R 3 and R 4 are as defined above.
• Carbon-carbon bond forming reactions for the preparation of cannabinoid compounds of Formula (III), Formula (IV), Formula (V) or Formula (VI) include but are not limited to catalytic and non-catalytic Ullman, Suzuki-Miyaura, Negishi, Kumada, Sonogashira and Stille reactions.
• a compound of Formula (I) or Formula (II) is contacted with a nucleophilic R 4 group, R 4 -W wherein R 4 is as defined above and is nucleophilic and W is an electrophilic group, such as a boron containing compound such as R 4 -B(OH) 2 , R 4 -B(OR)2 or R 4 -BF 3 K; or a Grignard compound such as R 4 - MgX; or an organozinc compound, such as R 4 -ZnX, in the presence or absence of a catalyst to produce a compound of Formula (III), Formula (IV), Formula (V) or Formula (VI).
• R 4 -W wherein R 4 is as defined above and is nucleophilic and W is an electrophilic group, such as a boron containing compound such as R 4 -B(OH) 2 , R 4 -B(OR)2 or R 4 -BF 3 K; or a Grignard compound such as R 4 - MgX; or an
• the catalytic system characterizing the process of the instant invention may comprise a base.
• said base can be any conventional base.
• non-limiting examples include: organic non-coordinating bases such as DBU, an alkaline or alkaline-earth metal carbonate, a carboxylate salt such as sodium or potassium acetate, or an alcoholate or hydroxide salt.
• Preferred bases are the alcoholate or hydroxide salts selected from the group consisting of the compounds of formula (RO)2M’ and ROM”, wherein M’ is an alkaline-earth metal, M” is an alkaline metal and R stands for hydrogen or a linear or branched alkyl group.
• the catalyst can be added to the reaction medium in a large range of concentrations.
• concentration values ranging from 0.001 % to 50 %, relative to the amount of substrate, thus representing respectively a substrate/catalyst (S/cat) ratio of 100,000 to 2.
• the complex concentration will be comprised between 0.01 % and 10 %, i.e. a S/cat ratio of 10,000 to 10 respectively.
• concentrations in the range of 0.1 to 5 %, corresponding to a S/cat ratio of 1000 to 20 respectively.
• useful quantities of base, added to the reaction mixture may be comprised in a relatively large range.
• non-limiting examples include: ranges between 1 to 100 molar equivalents relative to the substrate.
• base/substrate 1 to 3
• the catalytic reaction can be carried out in the presence or absence of a solvent.
• a solvent is required or used for practical reasons, then any solvent currently used in catalytic reactions can be used for the purposes of the invention.
• Non-limiting examples include aromatic solvents such as benzene, toluene or xylene, hydrocarbon solvents such as hexane or cyclohexane, ethers such as tetrahydrofuran, or yet primary or secondary alcohols, or water, or mixtures thereof.
• aromatic solvents such as benzene, toluene or xylene
• hydrocarbon solvents such as hexane or cyclohexane
• ethers such as tetrahydrofuran
• water or mixtures thereof.
• a person skilled in the art is well able to select the solvent most convenient in each case to optimize the catalytic reaction.
• the temperature at which the catalytic reaction can be carried out is comprised between -30 °C and 200 °C, more preferably in the range of between 0 °C and 100 °C.
• a person skilled in the art is also able to select the preferred temperature.
• Standard catalytic conditions typically implies the mixture of the substrate with the catalyst with or without a base, possibly in the presence of a solvent, and then treating such a mixture with the desired reactant at a chosen temperature in air or under an inert atmosphere of nitrogen or argon gas. Varying the reaction conditions, including for example, catalyst, temperature, solvent and reagent, to optimize the yield of the desired product would be well within the abilities of a person skilled in the art.
• the present disclosure also includes compounds of the Formula (X) which are benzyl cannabidiols having the following structure:
• R 2 and R 3 are as defined above in any paragraph for compounds of the Formula (II);
• R 5 and Re are one or more substitutents which are hydrogen, halo, -OR c , -NR C 2 , carboxylates (-COOR, where R is H or (Ci-Ce)-alkyl), phosphates, sulfates, a (Ci- C 2 o)-alkyl group, a (C 2 -C 2 o)-alkenyl group, a (C 2 -C 2 o)-alkynyl group, a (C 3 -C 20 )- cycloalkyl group, a (Ce-Ci 4 )-aryl group, or a (C 5 -Ci 4 )-heteroaryl group, wherein R c and R d are independently or simultaneously hydrogen, (Ci-C 2 o)-alkyl, (C 2 -C 20 )- alkenyl, or (C
• X is (Ci-Cio-alkylene) or (C2-Cio-alkenylene);
• R 5 and R 6 are one or more substitutents which are hydrogen, halo, a (Ci-Cio)-alkyl group, or a (Ce-Cio)-aryl group. In one embodiment, R 5 and R 6 are one or more substitutents which are hydrogen, halo, a (Ci-Ce)-alkyl group, or a phenyl group.
• X is (Ci-Ce-alkylene) or (C 2 -Ce-alkenylene). In another embodiment, X is (Ci-C 2 -alkylene) or (C 2 -alkenylene).
• the compound of the Formula (X) is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
• Triethylamine (108.3 g, 1.07 mole) was added to a mixture of 2-((1 R,6R)-3-methyl-6- (prop-1 -en-2-yl)cyclohex-2-enyl)benzene-1 ,3,5-triol (93.5 g, 308.8 mmol) in dichloromethane (900 ml) at room temperature while stirring.
• Solid N-Phenyl- bis(trifluoromethanesulfonimide) (1 18.61 g, 332 mmol) was added over 1.5 hours and the mixture was kept at room temperature using a water bath. The mixture was stirred at room temperature overnight then quenched with water (350 ml) and the phases separated.
• Triethylamine (10.8 g, 107 mmol) was added to a mixture of 2-((1 S,6R)-3-methyl-6- (prop-1 -en-2-yl)cyclohex-2-enyl)benzene-1 ,3,5-triol (9.35 g, 30.9 mmol) in dichloromethane (100 ml) at room temperature while stirring.
• Solid N-Phenyl- bis(trifluoromethanesulfonimide) (12.0 g, 33.6 mmol) was added over 1.5 hours and the mixture was kept at room temperature using a water bath. The mixture was stirred at room temperature overnight then quenched with water (40 ml) and the phases separated.
• Example 40 Preparation of 3,5-dihydroxy-4-((1S,6S)-3-methyl-6-(prop-1-en-2- yl)cyclohex-2-enyl)phenyl trifluoromethanesulfonate
• Example 46 Preparation of 5-heptyl-2-((1S,6S)-3-methyl-6-(prop-1-en-2- yl)cyclohex-2-enyl)benzene-1,3-diol (S,S-cannabidiphorol)
• Example 49 Preparation of (6aS,10aS)-6,6,9-trimethyl-3-propyl-6a,7,8,10a- tetrahydro-6H-benzo[c]chromen-1-ol (S,S-tetrahydrocannabivarin)
• Example 39 The mother liquor from Example 39 contained approximately 5% of 2-((1 R,6S)-3- methyl-6-(prop-1 -en-2-yl)cyclohex-2-enyl)benzene-1 ,3,5-triol. This was isolated using the procedure described in Example 30.
• Example 62 Preparation of (6aS,10aR)-6,6,9-trimethyl-3-phenethyl-6a,7,8,10a- tetrahydro-6H-benzo[c]chromen-1-ol (Perrottetinene)
• Example 65 Reaction of 3,5-dimethoxy-4-((1 R,6R)-3-methyl-6-(prop-1-en-2- yl)cyclohex-2-enyl)phenyl trifluoromethanesulfonate with n-propylzinc bromide
• Example 66 Reaction of 3,5-dimethoxy-4-((1 R,6R)-3-methyl-6-(prop-1-en-2- yl)cyclohex-2-enyl)phenyl trifluoromethanesulfonate with phenethylzinc bromide
• Triethylamine (31 ml, 222 mmol) was added to a solution of 2-((1 R,6R)-3-methyl-6- (prop-1 -en-2-yl)cyclohex-2-enyl)benzene-1 ,3,5-triol (38.5 g, 148 mmol) in dichloromethane (200 ml) and the mixture was cooled to 0 °C.
• a solution of toluenesulfonyl chloride (29.6 g, 155 mmol) was added slowly and the mixture allowed to warm to room temperature and stirred overnight. The reaction was quenched with saturated sodium bicarbonate solution and the phases separated.
• Triethylamine (3.1 ml, 22.2 mmol) was added to a solution of 2-((1 R,6R)-3-methyl-6- (prop-1 -en-2-yl)cyclohex-2-enyl)benzene-1 ,3,5-triol (3.85 g, 14.8 mmol) in dichloromethane (50 ml) and the mixture was cooled to 0 °C.
• a solution of trifluoromethanesulfonyl anhydride (4.51 g, 16.0 mmol) was added slowly and the mixture allowed to warm to room temperature and stirred overnight. The reaction was quenched with saturated sodium bicarbonate solution and the phases separated.
• Acetyl chloride (0.39 g, 4.94 mmol) was added to a mixture of 3,5-dihydroxy-4- ((1 R,6R)-3-methyl-6-(prop-1 -en-2-yl)cyclohex-2-enyl)phenyl 4-methylbenzene- sulfonate (1.0 g, 2.41 mmol) and NEt 3 (0.73 g, 7.24 mmol) in CH2CI2 (10 ml) at 0 °C under argon. The mixture was stirred at room temperature for 4 hours. The reaction was quenched with water and the phases separated.
• Acetyl chloride (2.05 g, 26.1 mmol) was added to a mixture of 3,5-dihydroxy-4- ((1 R,6R)-3-methyl-6-(prop-1 -en-2-yl)cyclohex-2-enyl)phenyl
• Example 80 Hydrolysis of (2-((1 R,6R)-3-methyl-6-(prop-1-en-2-yl)cyclohex-2- enyl)-5-propyl-1,3-phenylene)bis(oxy)bis(trimethylsilane)
• Example 83 Reaction of 3,5-dimethoxy-4-((1 R,6R)-3-methyl-6-(prop-1-en-2- yl)cyclohex-2-enyl)phenyl 4-methylbenzenesulfonate with n-pentylzinc bromide using [1,1'-Bis(diphenylphosphino)ferrocene]dichloropalladium(ll) chloride and zinc bromide as catalyst
• Example 84 Reaction of 3,5-dimethoxy-4-((1 R,6R)-3-methyl-6-(prop-1-en-2- yl)cyclohex-2-enyl)phenyl 4-methylbenzenesulfonate with n-pentylzinc bromide using [1,1'-Bis(diphenylphosphino)ferrocene]dichloropalladium(ll) chloride and zinc triflate as catalyst
• Example 85 Reaction of 3,5-dimethoxy-4-((1 R,6R)-3-methyl-6-(prop-1-en-2- yl)cyclohex-2-enyl)phenyl 4-methylbenzenesulfonate with n-pentylzinc bromide using [1,1'-Bis(diphenylphosphino)ferrocene]dichloropalladium(ll) chloride and copper(ll) bromide as catalyst
• Example 86 Reaction of 3,5-dimethoxy-4-((1 R,6R)-3-methyl-6-(prop-1-en-2- yl)cyclohex-2-enyl)phenyl 4-methylbenzenesulfonate with n-propylzinc bromide using [1,1'-Bis(diphenylphosphino)ferrocene]dichloropalladium(ll) chloride and zinc bromide as catalyst
• Example 87 Reaction of 3,5-dihydroxy-4-((1 R,6R)-3-methyl-6-(prop-1-en-2- yl)cyclohex-2-enyl)phenyl trifluoromethanesulfonate with n-pentylmagne-sium bromide using [1,1 '-Bis(diphenylphosphino)ferrocene]dichloro-palladium(ll) as catalyst
• Example 88 Reaction of 3,5-dihydroxy-4-((1 R,6R)-3-methyl-6-(prop-1-en-2- yl)cyclohex-2-enyl)phenyl trifluoromethanesulfonate with n-propylmagne-sium bromide using [1,1 '-Bis(diphenylphosphino)ferrocene]dichloro-palladium(ll) as catalyst
• Example 90 Reaction of 1,3-dimethoxy-2-((1 R,6R)-3-methyl-6-(prop-1-en-2- yl)cyclohex-2-enyl)-5-pentylbenzene with sodium ethylthiolate
• Example 92 Reaction of 1,3-dimethoxy-2-((1 R,6R)-3-methyl-6-(prop-1-en-2- yl)cyclohex-2-enyl)-5-propylbenzene with sodium dodecylthiolate
• Example 94 Reaction of 3,5-dihydroxy-4-((1 R,6R)-3-methyl-6-(prop-1-en-2- yl)cyclohex-2-enyl)phenyl trifluoromethanesulfonate with n-pentylmagne-sium bromide using bis(diphenylphosphino)ethane]nickel(ll) chloride as catalyst
• Example 97 Preparation of (6aR,10aR)-6,6,9-trimethyl-3-phenethyl-6a,7,10,10a- tetrahydro-6H-benzo[c]chromen-1-ol

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Crystallography & Structural Chemistry (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Priority Applications (11)

Applications Claiming Priority (4)

Publications (1)

Family

ID=73459164

Family Applications (1)

Country Status (11)

Cited By (12)

Families Citing this family (3)

Citations (1)

Family Cites Families (10)

• 2020
  • 2020-05-20 IL IL288196A patent/IL288196B2/en unknown
  • 2020-05-20 CA CA3179248A patent/CA3179248C/en active Active
  • 2020-05-20 CA CA3179235A patent/CA3179235A1/en active Pending
  • 2020-05-20 SG SG11202112677WA patent/SG11202112677WA/en unknown
  • 2020-05-20 US US17/613,936 patent/US20220220089A1/en active Pending
  • 2020-05-20 CA CA3141590A patent/CA3141590C/en active Active
  • 2020-05-20 KR KR1020217041775A patent/KR20220012298A/ko not_active Ceased
  • 2020-05-20 EP EP20810339.0A patent/EP3959193A4/en active Pending
  • 2020-05-20 CN CN202080043431.XA patent/CN114269717A/zh active Pending
  • 2020-05-20 AU AU2020280231A patent/AU2020280231A1/en active Pending
  • 2020-05-20 JP JP2022516247A patent/JP7654642B2/ja active Active
  • 2020-05-20 WO PCT/CA2020/050674 patent/WO2020232545A1/en not_active Ceased
  • 2020-05-20 MX MX2021014329A patent/MX2021014329A/es unknown

Patent Citations (1)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events